The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy remains the standard of care for patients with previously treated non-small cell lung cancer. However, few reports have compared the clinical benefits of second-line ICIs alone with those of ICIs combined with other therapies, including anti-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Zhang, Ting, Yang, Xue, Zhao, Jing, Xia, Lixia, Wang, Qiyuan, Jin, Rui, Zhou, Lingxiao, Zhang, Bin, Zhao, Jun, Li, Huijie, Li, Wen, Xia, Yang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213016/
https://ncbi.nlm.nih.gov/pubmed/34150659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.690093
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller